For patients with chronic hepatitis B virus (HBV) infection with virologic suppression with nucleoside or nucleotide a ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Chronic Venous Ulceration ...

But this research is not necessarily led by researchers with a primary interest and background in this field. As the immunomodulatory effects of more established cancer therapies (e.g. radiotherapy ...

The issuer is solely responsible for the content of this announcement.

At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver ...

Johnson & Johnson announces Carvykti demonstrated significantly higher rates of MRD negativity compared to standard therapies in CARTITUDE-4 study: San Diego Wednesday, December 1 ...

There are two cell therapies approved in this patient setting, Johnson & Johnson’s Carvykti and Bristol Myers Squibb's Abecma ...

Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.

H.C. Wainwright analyst Matthew Keller initiated coverage of GRI Bio (GRI) with a Buy rating and $10 price target GRI is a clinical stage ...

Dr Navya Verma Cancer is one of the most dreaded diseases of the 21th century and spreading further with continuance and increasing incidence. It is the third leading cause of death worldwide. It is a ...

Nuvig Therapeutics raises $161 million in Series B funding to advance novel immunomodulatory treatments for autoimmune ...